OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
CNBX
CNBX Pharmaceuticals Inc.
0.0094
-0.0002
-2.08%
0.0094 / 0.0095 (1 x 1)
#3 Bethesda Metro Center
Suite 700
Bethesda, MD 20814
Eyal Barad 52, is a co-founder of Cannabics Inc., founded in 2012, and is a core member of Cannabics Inc.'s management team and brings 20 years of executive managerial experience in successful technology and startup ventures. Mr. Barad received his BA in Economics & International Relations from the Hebrew University in Jerusalem in 1994, and an MBA with Honors from Haifa University in 2007
Eyal Barad 52, is a co-founder of Cannabics Inc., founded in 2012, and is a core member of Cannabics Inc.'s management team and brings 20 years of executive managerial experience in successful technology and startup ventures. Mr. Barad received his BA in Economics & International Relations from the Hebrew University in Jerusalem in 1994, and an MBA with Honors from Haifa University in 2007
None
500 Commercial Street
Suite 502K
Manchester, NH 03101
# 3 Bethesda Metro Center
Suite 700
Bethesda, MD 20814
CNBX Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company specializing in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. We combine the power of our proprietary technologies with the expertise of our leading scientists to unlock the medicinal properties of cannabis and its diversity of bioactive compounds. We have conducted thousands of tests on biopsies and cell lines in order to identify the physiologic impact of cannabinoids on cell cycle and cell death. Our core technology is a continuously evolving bioinformatics platform that utilizes high throughput screening technology, advanced data analytics, artificial intelligence and proprietary methodologies to rapidly examine the physiologic impact of multiple cannabinoid compounds on tumor cells.
The Company has its headquarters in Tel Aviv Israel, which is a 5 room leased office suite. Additionally the company has its laboratory in Rehovot, Israel. The Company utilizes its attorney's office space in Bethesda, Maryland free of charge or lease, which is sufficient to date.
